Selective high-affinity ligand antibody mimics for cancer diagnosis and therapy: Initial application to lymphoma/leukemia

Clinical Cancer Research

Volumn 13, Issue 18, 2007, Pages

  Balhorn, Rod ^a   Hok, Saphon ^a,b   Burke, Patricia A ^b   Lightstone, Felice C ^a   Cosman, Monique ^a   Zemla, Adam ^a   Mirick, Gary ^b   Perkins, Julie ^a   Natarajan, Arutselvan ^b   Corzett, Michele ^a   DeNardo, Sally J ^b   Albrecht, Huguette ^b   Gregg, Jeff P ^b   DeNardo, Gerry L ^b  

^a LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA DR ANTIGEN; HLA DR10 ANTIGEN; MONOCLONAL ANTIBODY LYM 1; UNCLASSIFIED DRUG;

ANTIGEN BINDING; COMPUTER MODEL; CONFERENCE PAPER; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; LEUKEMIA; LIGAND BINDING; LYMPHOCYTOMA; LYMPHOMA; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PREDICTION; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BINDING SITES; BIOMIMETIC MATERIALS; CELL LINE, TUMOR; CELL SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HLA-DR ANTIGENS; HUMANS; LIGANDS; LYMPHOMA, NON-HODGKIN; MODELS, MOLECULAR; STREPTAVIDIN;

EID: 34548648265     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1128     Document Type: Conference Paper

References (45)

1. Cheson B. Radioimmunotherapy of non-Hodgkin's lymphomas. Blood 2003;101:391-8.
2. DeNardo GL, O'Donnell RT, Oldham R K, DeNardo SJ. A revolution in the treatment of non-Hodgkin's lymphoma. Cancer Biother Radiopharm 1998;13: 213-23.
3. DeNardo GL. Treatment of non-Hodgkin's lymphoma (NHL) with radiolabeled antibodies (mAbs). Semin Nucl Med 2005;35:202-11.
4. Juweid ME. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice. J Nucl Med 2002;43:1507-29.
5. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002;20:2453-63.
6. 131I-labeled murine and humanized MN-14 anti-carcinoembryonic antigen (CEA) monoclonal antibodies. Gynecol Oncol 1997;67:259-71.
7. 131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma-phase I, phase II. study. Acta Oncol 1999;38:351-9.
8. Paganelli G, Grana C, Chinol M, et al. Antibody guided three step therapy for high grade glioma with yttrium-90 biotin. Eur J Nucl Med 1999;26:348-57.
9. 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies. Clin Cancer Res 2000;6:3855-63.
10. Shuker SB, Hajduk PJ, Meadows RP, Fesik SW. Discovering high-affinity ligands for proteins: SAR by NMR. Science 1996;174:531-4.
11. Kramer RH, Karpen JW. Spanning binding sites on allosteric proteins with polymer-linked ligand dimmers. Nature 1998;395:710-3.
12. Maly DJ, Choong IC, Ellman JA. Combinatorial target-guided ligand assembly: identification of potent subtype-selective c-Src inhibitors. Proc Natl Acad Sci U S A 2000;97:2419-24.
13. Kitov PI, Sadowska JM, Mulvey G, et al. Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands. Nature 2000;403:669-72.
14. Fan E, Zhang Z, Minke WE, Hou Z, Verlinde CLMJ, Hol WG. High-affinity pentavalent ligands of Escherichia coli heat-labile enterotoxin by modular structure-based design. J Am Chem Soc 2000;122:2663-4.
15. Mammen M, Choi, S-K, Whitesides GM. Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew Chem Int Ed 1998;37:2754-94.
16. Epstein AL, Marder RJ, Winter JN, et al. Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human-B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res 1987;47:830-40.
17. Rose LM, Gunasekera AH, DeNardo SJ, DeNardo GL, Meares CF. Lymphoma-selective antibody Lym-1 recognizes a discrete epitope on the light chain of HLA-DR10. Cancer Immunol Immunother 1996;43:26-30.
18. Rose LM, Deng CT, Scott SL, et al. Critical lym-1 Binding residues on polymorphic HLA-DR molecules. Mol Immunol 1999;36:789-97.
19. Ghosh P, Amaya M, Mellins E, Wiley DC. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 1995;378:457-62.
20. Smith KJ, Pyrdol J, Gauthier L, Wiley DC, Wucherpfennig KW. Crystal structure of HLA-DR2 (DRA *0101, DRB1 *1501) complexed with a peptide from human myelin basic protein. J Exp Med 1998;188:1511-20.
21. Bolin DR, Swain AL, Sarabu R, et al. Peptide and peptide mimetic inhibitors of antigen presentation by HLA-DR class II MHC molecules. Design, structure-activity relationships, and X-ray crystal structures. J Med Chem 2000;43:2135-48.
22. Jardetzky TS, Brown JH, Gorga JC, et al. 3-dimensional structure of a human class-II histocompatibility molecule complexed with superantigen. Nature 1994; 368:711-8.
23. Henrichsen D, Ernst B, Magnani JL, Wang W, Meyer B, Peters T. Bioaffinity NMR spectroscopy identification of an E-selection antagonist in a substance mixture by transfer NOE. Angew Chem Int Ed 1999;38: 98-102.
24. Cosman M, Lightstone FC, Krishnan VV, et al. Identification of novel small molecules that bind to two different sites on the surface of tetanus toxin C fragment. Chem Res Toxicol 2002;15:1218-28.
25. 1H-NMR studies on nucleotide binding to the sarcoplasmic reticulum Ca2+ ATPase. Determination of the conformations of bound nucleotides by the measurement of proton-proton transferred nuclear Overhauser enhancements. Eur J Biochem 1982;128:113-7.
26. Gronenborn AM, Clore GM. Conformation of NAD+ bound to yeast and horse liver alcohol dehydrogenase in solution. The use of the proton-proton transferred nuclear Overhauser enhancement. J Mol Biol 1982; 157:155-60.
27. Roberts GCK. The other kind of biological NMR - studies of enzyme substrate interactions. Neurochem Res 1996;21:1117-24.
28. Dalvit C, Fogliatto G, Stewart A, Veronesi M, Stockman B. WaterLOGSY as a method for primary NMR screening. J Biomol NMR 2001;21:349-59.
29. Mosnaim AD, Puente J, Saavedra R, Diamond S, Wolf ME. In vitro human plasma leucine(5)-enkephalin degradation is inhibited by a select number of drugs with the phenothiazine molecule in their chemical structure. Pharmacol 2003;67:6-13.
30. Hull SR, Bright A, Carraway KL, Abe M, Hayes DF, Kufe DW. Oligosaccharide differences in the DF3 sialomucin antigen from normal human milk and the BT-20 human breast carcinoma cell line. Cancer Commun 1989;1:261-7.
31. Lloyd KO, Burchell J, Kudryashov V, Yin BW, Taylor-Papadimitriou J. Demonstration of simpler and fewer glycan chains in tumor cells. Comparison of O-linked carbohydrate chains in MUC-1mucin from normal breast epithelial cell lines and breast carcinoma cell lines. Demonstration of simpler and fewer glycan chains intumorcells. J Biol Chem 1996;271:33325-34.
32. Murphy GP, Elgamal AA, Su SL, Bostwick DG, Holmes EH. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer 1998;83:2259-69.
33. Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 1998;52:637-40.
34. Lui H, Moy P, Kim S, et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular epithelium. Cancer Res 1997;57:3629-34.
35. Chang SS, Reuter VE, Heston WDW, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PMSA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999;59:3192-8.
36. Lundin J, Osterborg A. Advances in the use of monoclonal antibodies in the therapy of chronic lymphocytic leukemia. Semin Hematol 2004;41:234-45.
37. Mason DY, Stein H, Gerdes J, et al. Value of monoclonal anti-CD22 (p135) antibodies for the detection of normal and neoplastic B lymphoid cells. Blood 1987;69:836-40.
38. Fernandez-Rodriguez J, Andersson CX, Laos S, et al. The leukocyte antigen CD43 is expressed in different cell lines of nonhematopoietic origin. Tumour Biol 2002;23:193-201.
39. Leonard JP, Link BK. Immunotherapy of Non-Hodgkin's lymphoma with hLL2 (Epratuzumab, an anti-CD22 monoclonal antibody) and HuID10 (Apolizumab). Semin Oncol 2002;29:81-6.
40. Link BK, Kostelny SA, Cole MS, Fusselman WP, Tso JY, Weiner GJ. Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms. Int J Cancer 1998;77:251-6.
41. Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, et al. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res 2000;60:5237-43.
42. DeNardo GL, O'Donnell RT, Rose LM, Mirick GR, Kroger LA, DeNardo, SJ. Milestones in the development of Lym-1 therapy. Hybridoma 1999;18:1-11.
43. Wilder RB, DeNardo GL, DeNardo SJ. Radioimmunotherapy: recent results and future directions. J Clin Oncol 1996;14:1383-400.
44. Lightstone FC, Prieto MC, Singh AK, et al. The identification of novel small molecule ligands that bind to tetanus toxin. Chem Res Toxicol 2000;13:356-62.
45. Venclovas C. Comparative modeling of CASP4 target proteins: combining results of sequence search with three-dimensional structure assessment. Proteins Suppl 2001;5:47-54.